Aubrey de Grey (@aubreydegrey) is Cambridge researcher and Chief Science Officer of SENS Research Foundation focused on aging and extending human longevity. He proposes that the first human beings who will live to 1,000 years old have already been born.
In addition to his research, Aubrey is editor-in-chief of the academic journal Rejuvenation Research, author of The Mitochondrial Free Radical Theory of Aging (1999) and co-author of Ending Aging (2007). De Grey’s research focuses on whether regenerative medicine can prevent the aging process. He works on the development of what he calls “Strategies for Engineered Negligible Senescence” (SENS), a collection of proposed techniques to rejuvenate the human body and stop aging. To this end, he has identified seven types of molecular and cellular damage caused by essential metabolic processes. SENS is a proposed panel of therapies designed to repair this damage.
He has been interviewed by most major news sources, including CBS 60 Minutes, the BBC, The New York Times, Fortune Magazine, The Washington Post, TED, Popular Science, The Colbert Report, Time and the Skeptics’ Guide to the Universe.
In our wide-ranging conversation, we cover many things, including:
- Why Aubrey switched from studying AI to the science of human longevity
- The causes of aging and how we can “cure” them
- Why prevention is orders of magnitude more effective than intervention
- The reason Aubrey believes some humans today will live to be 1000 years old
- Why there isn’t enough funding or support currently for fighting aging
- The reason stem cell research is progressing rapidly and proving fruitful
- How caloric restriction effects metabolism and aging
- Why SENS often spins out businesses to further their aims
- The science of immortality
- How mainstream media has reacted to prospect of increasing lifespan
Like this? Be sure to jump over to FringeFM or subscribe via iTunes or Stitcher
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | Google Podcasts | Stitcher | RSS | FREE BONUSES